We are analyzing https://link.springer.com/article/10.1186/bcr3099.

Title:
Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells | Breast Cancer Research
Description:
Introduction The presence of circulating tumor cells (CTC) in breast cancer might be associated with stem cell-like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, to be able to disseminate and metastasize, CTC must be able to perform epithelial-mesenchymal transition (EMT). We studied the expression of three EMT markers and the stem cell marker ALDH1 in CTC from 502 primary breast cancer patients. Data were correlated with the presence of disseminated tumor cells (DTC) in the bone marrow (BM) and with clinicopathological data of the patients. Methods A total of 2 × 5 ml of blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the detection of EpCAM, MUC-1, HER2 and beta-Actin transcripts. The recovered c-DNA was additionally multiplex tested for three EMT markers [TWIST1, Akt2, phosphoinositide kinase-3 (PI3Kα)] and separately for the tumor stem cell marker ALDH1. The identification of EMT markers was considered positive if at least one marker was detected in the sample. Two BM aspirates from all patients were analyzed for DTC by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3. Results Ninety-seven percent of 30 healthy donor samples investigated were negative for EMT and 95% for ALDH1 transcripts, respectively. CTC were detected in 97/502 (19%) patients. At least one of the EMT markers was expressed in 29% and ALDH1 was present in 14% of the samples, respectively. Interestingly, 5% of the ALDH1-positive and 18% of the EMT-positive patients were CTC-negative based on the cut-off level determined for CTC-positivity applying the AdnaTest BreastCancer. DTC in the BM were detected in 107/502 (21%) patients and no correlation was found between BM status and CTC positivity (P = 0.41). The presence of CTC, EMT and ALDH1 expression was not correlated to any of the prognostic clinical markers. Conclusions Our data indicate that (1) a subset of primary breast cancer patients shows EMT and stem cell characteristics and (2) the currently used detection methods for CTC are not efficient to identify a subtype of CTC which underwent EMT. (3) The clinical relevance on prognosis and therapy response has to be further evaluated in a prospective trial.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

cancer, cells, breast, patients, ctc, tumor, article, pubmed, google, scholar, stem, cell, emt, cas, detection, markers, primary, circulating, metastatic, blood, aldh, data, expression, bone, clinical, res, dtc, marrow, analysis, positive, samples, adnatest, central, clin, chemotherapy, study, pcr, prognostic, authors, presence, detected, therapy, treatment, epithelialmesenchymal, transition, published, kasimirbauer, expressed, status, disease,

Topics {✒️}

perform epithelial-mesenchymal transition pten/akt/beta-catenin signaling mammary stem/progenitor cells epithelial-mesenchymal transition markers article download pdf real-time rt-pcr detection epithelial-mesenchymal transition blood-circulating tumour cells technicians silke dürr-stürzer egfr/her2/pi3k/akt pathway [16] disseminated tumour cells pten/mtor/stat3 pathway pten/akt/mtor pathway cytokeratin-19 mrna-positive cells pan-cytokeratin antibody a45 cell stem cell improve long-term survival circulating tumour cells decreased progression-free survival conventional anti-cancer therapies disseminated tumor cells multimarker rt-pcr assay pi3k/akt signaling kinases related subjects tumor stem cells article kasimir-bauer german consensus group metastatic breast cancer cancer stem cells methods patient population enriched epcam-positive fraction stem/progenitor cells cd44+/cd24-/low cells breast cancer stem stem cell preparations stem cell features stem cell characteristics full access early breast cancer breast tumor cells emt multiplex rt-pcr circulating tumor cells colorectal cancer patients success study group cd44+cd24lo phenotype privacy choices/manage cookies anti-cancer agents [47] human pancreatic cancer generated fragment size occult tumor cells

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
         description:The presence of circulating tumor cells (CTC) in breast cancer might be associated with stem cell-like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, to be able to disseminate and metastasize, CTC must be able to perform epithelial-mesenchymal transition (EMT). We studied the expression of three EMT markers and the stem cell marker ALDH1 in CTC from 502 primary breast cancer patients. Data were correlated with the presence of disseminated tumor cells (DTC) in the bone marrow (BM) and with clinicopathological data of the patients. A total of 2 × 5 ml of blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the detection of EpCAM, MUC-1, HER2 and beta-Actin transcripts. The recovered c-DNA was additionally multiplex tested for three EMT markers [TWIST1, Akt2, phosphoinositide kinase-3 (PI3Kα)] and separately for the tumor stem cell marker ALDH1. The identification of EMT markers was considered positive if at least one marker was detected in the sample. Two BM aspirates from all patients were analyzed for DTC by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3. Ninety-seven percent of 30 healthy donor samples investigated were negative for EMT and 95% for ALDH1 transcripts, respectively. CTC were detected in 97/502 (19%) patients. At least one of the EMT markers was expressed in 29% and ALDH1 was present in 14% of the samples, respectively. Interestingly, 5% of the ALDH1-positive and 18% of the EMT-positive patients were CTC-negative based on the cut-off level determined for CTC-positivity applying the AdnaTest BreastCancer. DTC in the BM were detected in 107/502 (21%) patients and no correlation was found between BM status and CTC positivity (P = 0.41). The presence of CTC, EMT and ALDH1 expression was not correlated to any of the prognostic clinical markers. Our data indicate that (1) a subset of primary breast cancer patients shows EMT and stem cell characteristics and (2) the currently used detection methods for CTC are not efficient to identify a subtype of CTC which underwent EMT. (3) The clinical relevance on prognosis and therapy response has to be further evaluated in a prospective trial.
         datePublished:2012-01-20T00:00:00Z
         dateModified:2012-01-20T00:00:00Z
         pageStart:1
         pageEnd:9
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr3099
         keywords:
            Metastatic Breast Cancer
            Cancer Stem Cell
            Circulate Tumor Cell
            Metastatic Breast Cancer Patient
            Disseminate Tumor Cell
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3099/MediaObjects/13058_2011_2899_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3099/MediaObjects/13058_2011_2899_Fig2_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Sabine Kasimir-Bauer
               affiliation:
                     name:University Hospital of Essen, University of Duisburg-Essen
                     address:
                        name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Oliver Hoffmann
               affiliation:
                     name:University Hospital of Essen, University of Duisburg-Essen
                     address:
                        name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Diethelm Wallwiener
               affiliation:
                     name:University Hospital of Tuebingen
                     address:
                        name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rainer Kimmig
               affiliation:
                     name:University Hospital of Essen, University of Duisburg-Essen
                     address:
                        name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tanja Fehm
               affiliation:
                     name:University Hospital of Tuebingen
                     address:
                        name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
      description:The presence of circulating tumor cells (CTC) in breast cancer might be associated with stem cell-like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, to be able to disseminate and metastasize, CTC must be able to perform epithelial-mesenchymal transition (EMT). We studied the expression of three EMT markers and the stem cell marker ALDH1 in CTC from 502 primary breast cancer patients. Data were correlated with the presence of disseminated tumor cells (DTC) in the bone marrow (BM) and with clinicopathological data of the patients. A total of 2 × 5 ml of blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the detection of EpCAM, MUC-1, HER2 and beta-Actin transcripts. The recovered c-DNA was additionally multiplex tested for three EMT markers [TWIST1, Akt2, phosphoinositide kinase-3 (PI3Kα)] and separately for the tumor stem cell marker ALDH1. The identification of EMT markers was considered positive if at least one marker was detected in the sample. Two BM aspirates from all patients were analyzed for DTC by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3. Ninety-seven percent of 30 healthy donor samples investigated were negative for EMT and 95% for ALDH1 transcripts, respectively. CTC were detected in 97/502 (19%) patients. At least one of the EMT markers was expressed in 29% and ALDH1 was present in 14% of the samples, respectively. Interestingly, 5% of the ALDH1-positive and 18% of the EMT-positive patients were CTC-negative based on the cut-off level determined for CTC-positivity applying the AdnaTest BreastCancer. DTC in the BM were detected in 107/502 (21%) patients and no correlation was found between BM status and CTC positivity (P = 0.41). The presence of CTC, EMT and ALDH1 expression was not correlated to any of the prognostic clinical markers. Our data indicate that (1) a subset of primary breast cancer patients shows EMT and stem cell characteristics and (2) the currently used detection methods for CTC are not efficient to identify a subtype of CTC which underwent EMT. (3) The clinical relevance on prognosis and therapy response has to be further evaluated in a prospective trial.
      datePublished:2012-01-20T00:00:00Z
      dateModified:2012-01-20T00:00:00Z
      pageStart:1
      pageEnd:9
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr3099
      keywords:
         Metastatic Breast Cancer
         Cancer Stem Cell
         Circulate Tumor Cell
         Metastatic Breast Cancer Patient
         Disseminate Tumor Cell
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3099/MediaObjects/13058_2011_2899_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3099/MediaObjects/13058_2011_2899_Fig2_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Sabine Kasimir-Bauer
            affiliation:
                  name:University Hospital of Essen, University of Duisburg-Essen
                  address:
                     name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Oliver Hoffmann
            affiliation:
                  name:University Hospital of Essen, University of Duisburg-Essen
                  address:
                     name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Diethelm Wallwiener
            affiliation:
                  name:University Hospital of Tuebingen
                  address:
                     name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rainer Kimmig
            affiliation:
                  name:University Hospital of Essen, University of Duisburg-Essen
                  address:
                     name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tanja Fehm
            affiliation:
                  name:University Hospital of Tuebingen
                  address:
                     name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:14
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Hospital of Essen, University of Duisburg-Essen
      address:
         name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
         type:PostalAddress
      name:University Hospital of Essen, University of Duisburg-Essen
      address:
         name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
         type:PostalAddress
      name:University Hospital of Tuebingen
      address:
         name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
         type:PostalAddress
      name:University Hospital of Essen, University of Duisburg-Essen
      address:
         name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
         type:PostalAddress
      name:University Hospital of Tuebingen
      address:
         name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Sabine Kasimir-Bauer
      affiliation:
            name:University Hospital of Essen, University of Duisburg-Essen
            address:
               name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Oliver Hoffmann
      affiliation:
            name:University Hospital of Essen, University of Duisburg-Essen
            address:
               name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
               type:PostalAddress
            type:Organization
      name:Diethelm Wallwiener
      affiliation:
            name:University Hospital of Tuebingen
            address:
               name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
               type:PostalAddress
            type:Organization
      name:Rainer Kimmig
      affiliation:
            name:University Hospital of Essen, University of Duisburg-Essen
            address:
               name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
               type:PostalAddress
            type:Organization
      name:Tanja Fehm
      affiliation:
            name:University Hospital of Tuebingen
            address:
               name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
      name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
      name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany
      name:Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
      name:Department of Gynecology and Obstetrics, University Hospital of Tuebingen, Tuebingen, Germany

External Links {🔗}(189)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.79s.

LINK . SPRINGER . COM {}